

Additional file 2

Cost-effectiveness results with separate effects for men and women

Table 1. Lifetime costs, health gain and cost-effectiveness of cardiovascular disease prevention in Australia.

	Lifetime health gain (QALYs)	Lifetime intervention costs to Government (\$billion)	Lifetime intervention costs to Patients (\$billion)	Lifetime treatment costs averted (\$billion)	Cost-effectiveness (\$/QALY)
Current practice	260,000 (200,000 to 310,000)	\$12 (\$12 to \$12)	\$2.6 (\$2.6 to \$2.6)	-\$3.2 (-\$4.4 to -\$2.2)	\$42,000 (\$33,000 to \$59,000)
Existing single risk factor-based guidelines	170,000 (100,000 to 250,000)	\$7.4 (\$5.2 to \$9.9)	\$3.5 (\$2.5 to \$4.6)	-\$2.2 (-\$3.4 to -\$1.2)	\$50,000 (\$38,000 to \$75,000)
Absolute risk (≥15%)	65,000 (44,000 to 90,000)	\$1.3 (\$0.9 to \$1.8)	\$0.7 (\$0.5 to \$1.0)	-\$0.6 (-\$1.0 to -\$0.4)	\$22,000 (\$18,000 to \$28,000)
Absolute risk (≥10%)	140,000 (96,000 to 200,000)	\$3.5 (\$2.5 to \$4.6)	\$1.9 (\$1.4 to \$2.5)	-\$1.5 (-\$2.2 to -\$0.9)	\$27,000 (\$22,000 to \$35,000)
Absolute risk (≥5%)					
– including statins <10%	320,000 (220,000 to 440,000)	\$10.0 (\$7.2 to \$14.0)	\$5.5 (\$3.9 to \$7.3)	-\$3.6 (-\$5.4 to -\$2.1)	\$38,000 (\$32,000 to \$48,000)
– excluding statins <10%	280,000 (190,000 to 390,000)	\$6.5 (\$4.5 to \$8.6)	\$4.3 (\$3.0 to \$5.6)	-\$3.1 (-\$4.7 to -\$1.9)	\$27,000 (\$21,000 to \$34,000)
Absolute risk (≥5%) assuming the cheaper price of statins in New Zealand					
– including statins <10%	320,000 (220,000 to 440,000)	\$5.1 (\$3.6 to \$6.8)	\$3.7 (\$2.6 to \$4.9)	-\$3.6 (-\$5.4 to -\$2.1)	\$16,000 (\$12,000 to \$22,000)
– excluding statins <10%	280,000 (190,000 to 390,000)	\$4.7 (\$3.3 to \$6.2)	\$3.6 (\$2.6 to \$4.8)	-\$3.1 (-\$4.7 to -\$1.9)	\$19,000 (\$14,000 to \$25,000)

NB. All values are rounded to two significant figures. Health gains and costs are presented as mean and 95% uncertainty interval, and cost-effectiveness ratio as median and 95% uncertainty interval. Costs are presented in 2008 Australian dollars. QALY – quality-adjusted life year




Figure 1 Cost-effectiveness of cardiovascular disease prevention